A- A A+

Non-fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using linked primary care, secondary care and mortality records.

Domzaridou, E, Carr, MJ, Millar, T, Webb, RT, Ashcroft, DM. 

Addiction. 2023. doi.org/10.1111/add.16306


Psychopharmaka-Interaktionen in der Suchttherapie

ÖGABS 2023

Mag. pharm. Sonja Habib-MayeraHPh, Klinische Pharmazie, KH-Apotheke amNeuromedCampus Kepler Universitätsklinikum, Linz



Variation in adverse drug events of opioids in the United States. 

Liu EY, McCall KL, Piper BJ. 

Front Pharmacol. 2023 Mar 24;14:1163976. doi: 10.3389/fphar.2023.1163976. PMID: 37033633; PMCID: PMC10079914.


Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study. 

Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. 

J Subst Use Addict Treat. 2023 Mar 30:209031. doi: 10.1016/j.josat.2023.209031. Epub ahead of print. PMID: 37003540.


Potenziell inadäquate Medikation für ältere Menschen: PRISCUS 2.0 - Erste Aktualisierung der PRISCUS-Liste

Potentially inadequate medications in the elderly: PRISCUS 2.0—first update of the PRISCUS list

Mann, Nina-Kristin; Mathes, Tim; Sönnichsen, Andreas; Pieper, Dawid; Klager, Elisabeth; Moussa, Mahmoud; Thürmann, Petra A.

Dtsch Arztebl Int 2023; 120: 3-10; DOI: 10.3238/arztebl.m2022.0377


A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity. 

Traver EC, Heil EL, Schmalzle SA. 

Open Forum Infect Dis. 2022 Jul 1;9(7):ofac331. doi: 10.1093/ofid/ofac331. PMID: 35899282; PMCID: PMC9310287.


Identifying clinically relevant drug-drug interactions with methadone and buprenorphine: a translational approach to signal detection. 

Miano TA, Wang L, Leonard CE, Brensinger CM, Acton EK, Dawwas GK, Bilker WB, Soprano SE, Pham Nguyen TP, Woody G, Yu E, Neuman M, Li L, Hennessy S. 

Clin Pharmacol Ther. 2022 Jul 26. doi: 10.1002/cpt.2717. Epub ahead of print. PMID: 35881659.



New app shows how cannabinoids could interact with other medications

A new web-based application developed by Penn State researchers could help pharmacists and other health care providers improve patient safety by reducing unintended interactions between medical and recreational marijuana and cannabidiol (CBD) products and other medications. Penn State College of Medicine researchers said that medical marijuana and CBD have become more accessible to consumers through local retail stores, pharmacies or even by illicit means, and that these products may affect the metabolism of other medications. (Pennsylvania State University, USA, 06.04.2022)


Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. 

Lopera V, Rodríguez A, Amariles P. 

J Clin Med. 2022 Feb 22;11(5):1154. doi: 10.3390/jcm11051154. PMID: 35268245; PMCID: PMC8911401.


Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. 

Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF. 

CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):30-43. doi: 10.1002/psp4.12730. Epub 2021 Nov 17. PMID: 34791831; PMCID: PMC8752107.


Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions

Shamema Nasrin, Christy J.W. Watson, Yadira X Perez-Paramo and Philip Lazarus

Drug Metabolism and Disposition December 2021, 49 (12) 1070-1080; DOI: doi.org/10.1124/dmd.121.000442 


Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites

Shamema Nasrin, Christy J. W. Watson, Keti Bardhi, Gabriela Fort, Gang Chen and Philip Lazarus

Drug Metabolism and Disposition December 2021, 49 (12) 1081-1089; DOI: doi.org/10.1124/dmd.121.000530 


Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study. 

Bart G, Giang LM, Yen H, Hodges JS, Brundage RC. 

Drug Alcohol Depend. 2021 Oct 1;227:109025. doi: 10.1016/j.drugalcdep.2021.109025. Epub 2021 Sep 1. PMID: 34482033.



Evaluation of drug-drug interactions in hospitalized patients on medications for OUD. 

Berger O, Rector K, Meredith J, Sebaaly J. 

Ment Health Clin. 2021 Jul 16;11(4):231-237. doi: 10.9740/mhc.2021.07.231. PMID: 34316418; PMCID: PMC8287868.


Adverse drug reactions with naltrexone: Experience from an addiction treatment center. 

Sarkar S, Addagadda SS, Bhatia G, Chadda RK. 

Indian J Psychiatry. 2021 Mar-Apr;63(2):206-207. doi: 10.4103/psychiatry.IndianJPsychiatry_94_20. Epub 2021 Apr 14. PMID: 34194072; PMCID: PMC8214125.


Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance. 

Ershad M, Cruz MD, Mostafa A, Mckeever R, Vearrier D, Greenberg MI. 

J Addict Med. 2020 Mar/Apr;14(2):172-174. doi: 10.1097/ADM.0000000000000535. PMID: 31206401.



Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. 

Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P 

Biomed Res Int. 2020 Aug 13;2020:3902740. doi: 10.1155/2020/3902740. PMID: 32855964; PMCID: PMC7443220.


Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. 

Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), 

Clinical Pharmacology in Drug Development. doi.org/10.1002/cpdd.934


Opioids and antidepressants: which combinations to avoid. 

Perananthan V, Buckley NA. 

Aust Prescr 2021;44:41-4. doi.org/10.18773


Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. 

Gao LH, Nie QH, Zhao XT. 

Int J Gen Med. 2021 Jan 28;14:289-301. doi: 10.2147/IJGM.S283910. PMID: 33536776; PMCID: PMC7850569.


Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes. 

Gnanapandithan K, Karthik N, Gerber J. 

Clin Pract. 2021 Feb 7;11(1):101-105. doi: 10.3390/clinpract11010015. PMID: 33562182; PMCID: PMC7931031.


Comparison of two algorithms to support medication surveillance for drug-drug interactions between QTc-prolonging drugs. 

Berger FA, van der Sijs H, van Gelder T, Kuijper AFM, van den Bemt PMLA, Becker ML. 

Int J Med Inform. 2021 Jan;145:104329. doi: 10.1016/j.ijmedinf.2020.104329. Epub 2020 Nov 4. PMID: 33181445.


Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents. 

Hong J, Wright RC, Partovi N, Yoshida EM, Hussaini T. 

J Clin Transl Hepatol. 2020 Sep 28;8(3):322-335. doi: 10.14218/JCTH.2020.00034. Epub 2020 Jul 30. PMID: 33083256; PMCID: PMC7562806.


Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol. 

Madden K, Tanco K, Bruera E. Clinically 

Pediatrics. 2020;145(6):e20193256. doi:10.1542/peds.2019-3256



Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions.

Brown, J.D. 

J. Clin. Med. 2020, 9, 919.


Leberzirrhose: Empfehlungen zur sicheren Anwendung von Arzneimitteln

Berlin – Eine Leberzirrhose bei einem Patienten kann bekanntlich den Stoffwechsel und die Dosis-Wirkungsbeziehung von Arzneimitteln verändern und das Risiko von Nebenwirkungen erhöhen. Eine niederländische Arbeitsgruppe hat nun evidenzbasierte Empfehlungen für den Einsatz und die Dosierung zahlreicher praxisrelevanter Arzneimittel bei Leberzirrhose erarbeitet. (aerzteblatt.de, 04.02.2020)


Direct‐acting antivirals interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients.

Ing Lorenzini, K, Girardin, F. 

Liver Int. 2020; 40: 32– 44. doi.org/10.1111/liv.14283


Wechselwirkungen mit HCV-DAA-Medikamenten – Update on hep-druginteractions.org

We have added some new comedications to the interaction checker, at the request of some of our users. You can now look up interactions with alcohol, cannabidiol (CBD), carfentanil, clofazimine, heroin and mesna. (The University of Liverpool’s HEP Drug Interactions Checker, UK, 06.01.2020)


Improving Recognition and Reporting of Adverse Drug Reactions in the NICU: A Quality Improvement Project.

Cammack B, Oschman A, Lewis T.

Pediatr Qual Saf. 2019 Aug 30;4(5):e203. doi: 10.1097/pq9.0000000000000203.


Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients.

Ing Lorenzini K, Girardin F.

Liver Int. 2019 Oct 26. doi: 10.1111/liv.14283.